Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CPA3 | P15088 | 3/20 | 0.60 |
| ▸ | PTGES | O14684 | 2/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.58 |
| ▸ | PPARG | P37231 | 2/20 | 0.58 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 10/20 | 0.55 |
| ▸ | MMP1 | P03956 | 5/20 | 0.55 |
| ▸ | MMP3 | P08254 | 5/20 | 0.55 |
| ▸ | CPA1 | P15085 | 2/20 | 0.54 |
| ▸ | CPB1 | P15086 | 1/20 | 0.54 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.54 |
| ▸ | MMP7 | P09237 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10957172 | 1.00 | FOLH1 (0.66) | FOLH1CYP1A2CPA3PTGESALOX5 | |
| SCHEMBL3242850 | 1.00 | FOLH1 (0.66) | FOLH1CYP1A2CPA3PTGESALOX5 | |
| SCHEMBL10955140 | 1.00 | FOLH1 (0.66) | FOLH1CYP1A2CPA3PTGESALOX5 | |
| SCHEMBL9653477 | 1.00 | FOLH1 (0.66) | FOLH1CYP1A2CPA3PTGESALOX5 | |
| SCHEMBL10960336 | 1.00 | FOLH1 (0.66) | FOLH1CYP1A2CPA3PTGESALOX5 | |
| SCHEMBL8555594 | 1.00 | FOLH1 (0.66) | FOLH1CYP1A2CPA3PTGESALOX5 | |
| SCHEMBL9653480 | 1.00 | FOLH1 (0.66) | FOLH1CYP1A2CPA3PTGESALOX5 | |
| SCHEMBL9655121 | 1.00 | FOLH1 (0.66) | FOLH1CYP1A2CPA3PTGESALOX5 | |
| SCHEMBL9209348 | 1.00 | FOLH1 (0.66) | FOLH1CYP1A2CPA3PTGESALOX5 | |
| SCHEMBL10550611 | 1.00 | FOLH1 (0.66) | FOLH1CYP1A2CPA3PTGESALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160089318-A1 | PERSONAL CARE COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS | THE PROCTER & GAMBLE COMPANY | 2016-03-31 | — | — | US | claimed |
| EP-1793871-A2 | NON-ABSORBENT AND ABSORBENT ARTICLES FOR INHIBITING THE PRODUCTION OF EXOPROTEINS | Kimberly-Clark Worldwide, Inc. (US) | 2007-06-13 | — | — | EP | claimed |
| WO-2006038980-A2 | NON-ABSORBENT AND ABSORBENT ARTICLES FOR INHIBITING THE PRODUCTION OF EXOPROTEINS | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2006-04-13 | — | — | WO | claimed |
| US-20060067991-A1 | Non-absorbent articles for inhibiting the production of exoproteins | KIMBERLY-CLARK WORLDWIDE, INC. | 2006-03-30 | — | — | US | claimed |
| US-20060067990-A1 | Absorbent articles for inhibiting the production of exoproteins | KIMBERLY-CLARK WORLDWIDE, INC. | 2006-03-30 | — | — | US | claimed |
| CN-114853828-A | Compounds, conjugates and uses thereof | 阿格纳生物制药有限公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-108699558-B | Nucleic acid complexes | 协和麒麟株式会社 | 2021-12-07 | — | — | CN | disclosed |
| CN-113286600-A | Nucleic acid complexes | 协和麒麟株式会社 | 2021-08-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060067990-A1 | Absorbent articles for inhibiting the production of exoproteins | SLC43A1, MRPL21, SLC7A5 | FOLH1 584/4885CYP1A2 3032/4885CPA3 2092/4885 |
| US-20060067991-A1 | Non-absorbent articles for inhibiting the production of exoproteins | SLC43A1, MRPL21, SLC7A5 | FOLH1 449/4885CYP1A2 2988/4885CPA3 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.